Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment

Betsy Goodfellow | November 23, 2023 | News story | Medical Communications Gastrointestinal tract, Landos Biopharma, clinical trial, ulcerative colitis 

Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results for the NX-13 phase 1b trial for patients with ulcerative colitis (UC), having published this data in the Journal of Crohn’s and Colitis.

The trial included 38 patients, with the patients randomised to either receive various doses of the NX-13 or a placebo. NX-13 was well-tolerated in all patients, with no deaths or severe adverse events reported, and only mild to moderate adverse events being observed.

Most patients who received the drug for four weeks showed consistent and rapid clinical improvement in total Mayo score and in symptomatic relief. Endoscopic improvement was observed to correlate closely with symptom improvement.

The drug is now being assessed in the NEXUS trial – a randomised, multi-centre, double-blind, placebo-controlled, multiple dose, statistically powered, phase 2 proof-of-concept study. Results are expected in the fourth quarter of 2024.

Bram Verstockt MD PhD, lead author on the publication, commented: “Despite advances in UC treatments, the need for new and novel therapies such as NX-13 remains highly important for patients. The early signs of efficacy, along with a favorable safety profile, highlighted in this publication are encouraging. I am excited about the potential of NX-13 and immunometabolism in breaking the inflammatory cycle in UC, which remains a significant unmet need in effectively treating patients.”

Betsy Goodfellow

Related Content

Vertex shares results from phase 1/2 trial of type 1 diabetes treatment

Vertex Pharmaceuticals has announced new data from its phase 1/2 clinical trial of VX-880, an …

Gilead shares phase 3 results from HIV prevention trial

Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE …

Takeda shares data from phase 3 trial of CIPD treatment

Takeda has announced data from the phase 3 ADVANCE-CIDP 3 trial, which assessed the safety …

Latest content